Multidrug resistance in aggressive lymphoproliferative disorders of T and natural-killer origin.
暂无分享,去创建一个
B. Drénou | R. Fauchet | T. Lamy | L. Amiot | P. Le Prisé | P. Le Prise | Renée Fauchet | Thierry Lamy | Renée Fauchet | Bernard Drenou | Laurence Amiot | P.-Y. Le Prise | P. L. Prise
[1] C. Leith,et al. Multidrug resistance in leukemia , 1998, Current opinion in hematology.
[2] J. Chan,et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. , 1997, Blood.
[3] A. Chiang,et al. CD56+ NK lymphomas:clinicopathological features and prognosis , 1997, British journal of haematology.
[4] J. Diebold,et al. CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. , 1997, Blood.
[5] R. Fanin,et al. P‐glycoprotein (PGP) and lung resistance‐related protein (LRP) expression and function in leukaemic blast cells , 1997, British journal of haematology.
[6] K. Oshimi,et al. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. , 1997, Blood.
[7] Philip R. Cohen,et al. Mycosis fungoides and Sezary syndrome. , 1996, Blood.
[8] M. Davey,et al. Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells. , 1996, Leukemia research.
[9] G. Raghu,et al. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. , 1996, Experimental hematology.
[10] W. Erber,et al. The detection of rhodamine 123 efflux at low levels of drug resistance , 1996, British journal of haematology.
[11] G. Raghu,et al. The multidrug resistance phenotype confers immunological resistance , 1996, The Journal of experimental medicine.
[12] C. Scott,et al. Clinical and laboratory characteristics of chronic natural killer cell lymphocytosis. , 1996, Blood.
[13] P. Gaulard,et al. CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. , 1996, Blood.
[14] E. Jaffe,et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. , 1996, The American journal of surgical pathology.
[15] M. Fukumoto,et al. Frequent expression of P‐glycoprotein/MDR1 by nasal T‐cell lymphoma cells , 1995, Cancer.
[16] A Orfao,et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.
[17] C. Jacquelinet,et al. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. , 1995, Leukemia.
[18] H. Clevers,et al. The drug resistance-related protein LRP is the human major vault protein , 1995, Nature Medicine.
[19] E. Paietta,et al. Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Eastern Cooperative Oncology Group. , 1995, Blood reviews.
[20] B I Sikic,et al. Multidrug resistance in lymphomas. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Tefferi,et al. Chronic natural killer cell lymphocytosis: a descriptive clinical study. , 1994, Blood.
[22] P. Sonneveld,et al. High expression of the multidrug resistance‐associated protein (MRP) in chronic and prolymphocytic leukaemia , 1994, British journal of haematology.
[23] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[24] P. Sonneveld,et al. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. , 1994, Leukemia.
[25] O. Fardel,et al. Detection of P glycoprotein activity on normal and leukemic CD34+ cells. , 1993, Leukemia research.
[26] T. Loughran,et al. Clonal diseases of large granular lymphocytes. , 1993, Blood.
[27] P. Gaulard,et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. , 1993, Blood.
[28] R. Arceci. Clinical significance of P-glycoprotein in multidrug resistance malignancies [editorial] [see comments] , 1993 .
[29] M. Slovak,et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. , 1993, Cancer research.
[30] T. Tsuruo,et al. Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte-proliferative disorders. , 1993, Blood.
[31] S. McKenna,et al. MULTIDRUG RESISTANCE IN LEUKAEMIA , 1997, Bailliere's clinical haematology.
[32] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[33] J. Chan,et al. CD56 (NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. , 1992, Human pathology.
[34] T. Grogan,et al. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. , 1992, Blood.
[35] D. Catovsky,et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. , 1991, Blood.
[36] J. Coon,et al. Multidrug resistance activity in human lymphocytes. , 1991, Human immunology.
[37] I. Roninson,et al. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.
[38] H. Dohy,et al. Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature POSSIBLE EXISTENCE OF A NEW CLINICAL ENTITY ORIGINATING FROM THE THIRD LINEAGE OF LYMPHOID CELLS , 1990, British journal of haematology.
[39] F. Galibert,et al. Analysis of junctional diversity in the preferential V delta 1-J delta 1 rearrangement of fresh T-acute lymphoblastic leukemia cells by in vitro gene amplification and direct sequencing , 1989 .
[40] A. Neyfakh. Use of fluorescent dyes as molecular probes for the study of multidrug resistance. , 1988, Experimental cell research.
[41] T. Tsuruo,et al. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[42] I. Pastan,et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[43] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[44] Prof. Dr. Dr. h.c. mult. Karl Lennert,et al. Histopathologie der Non-Hodgkin-Lymphome , 1981, Springer Berlin Heidelberg.